A quick peek into the report
Table of Contents
1.1. | Scope of the Report |
1.2. | Global Cancer Imaging Systems Market Segmentation |
1.3 | Key Learnings |
1.4 | Research Methodology |
1.4.1. | Data Triangulation |
1.4.2. | Key Data Points from Secondary Sources |
1.4.3. | Secondary Data Sources |
1.4.4. | Key Data Points From Primary Sources |
1.4.5. | Top-Down Approach (Segmental Analysis) |
1.4.6. | Bottom-Up Approach (Segmental Analysis) |
1.4.7. | Assumptions and Limitations |
1.4.8 | Data and Prediction Modelling |
2.1 | Overview |
2.2 | Important Facts |
2.3 | Estimated Number of New Cases of Cancer and Deaths by Gender, U.S., 2017 |
2.4 | Discovery of Medical Imaging Modalities |
2.5 | Developments in imaging modalities |
2.6 | Role of Imaging in Oncology Decision Process |
2.7 | Radiation Risk |
2.8 | Potential Benefits & Risks of Medical Imaging |
2.9 | Recent Developments |
3.1 | Overview |
3.2 | Market Drivers |
3.3. | Market Challenges |
3.4 | Market Opportunities |
4.1. | Key Development and Strategies |
4.1.1 | New Product Launches and Developments |
4.1.2 | Patents, Approvals and Certifications |
4.1.3 | Business Expansions/Contracts |
4.1.4 | Collaborations, Joint Ventures and Partnerships |
4.1.5 | Others |
4.2. | Emerging Trends in Medical Imaging Technology |
4.3 | Legal Requirements and Regulations |
4.4 | Market Share Analysis |
4.5 | Analysis |
4.6 | Growth Share Matrix |
4.7 | Analysis |
5.1 | Patent Landscape |
5.2. | Consortiums, Associations, and Regulatory Bodies |
5.3 | Analysis- Assumption & Limitations |
6.1. | Overview |
6.2 | Mammography |
6.2.1 | Analog Mammography |
6.2.2 | Full Field Digital Mammography |
6.2.3 | Digital Breast Tomosynthesis (DBT) |
6.2.4 | Some of the Key Market Players |
6.3 | Computed Tomography |
6.4 | Molecular Breast Imaging (MBI) |
6.5 | Magnetic Resonance Imaging (MRI) |
6.6 | Positron Emission Tomography (PET) |
6.7 | Ultrasound |
6.8 | Others |
7.1 | Overview |
7.2 | Breast Cancer |
7.3 | Lung Cancer |
7.4 | Prostate Cancer |
7.5 | Colorectal Cancer |
7.6 | Liver Cancer |
7.7 | Other Cancers |
8.1 | Overview |
8.2 | Hospitals |
8.3 | End-User |
8.4 | Others |
9.1 | Overview |
9.2 | North America |
9.2.1 | North America by Country Analysis |
9.2.2 | The U.S. |
9.2.3 | Canada |
9.3 | Europe |
9.3.1 | Europe by Country Analysis |
9.3.2 | Germany |
9.3.3 | France |
9.3.4 | The U.K. |
9.3.5 | Italy |
9.3.6 | Spain |
9.3.7 | Netherlands |
9.3.8 | Belgium |
9.3.9 | Rest of Europe |
9.4 | Asia-Pacific |
9.4.1 | Asia-Pacific by Country Analysis |
9.4.2 | Japan |
9.4.3 | China |
9.4.4 | Australia |
9.4.5 | South Korea |
9.4.6 | India |
9.4.7 | Malaysia |
9.4.8 | Indonesia |
9.4.9 | Rest of Asia-Pacific |
9.5 | Latin America |
9.5.1 | Latin America by Country Analysis |
9.5.2 | Brazil |
9.5.3 | Mexico |
9.5.4 | Rest of Latin America |
9.6 | Rest of World (RoW) |
9.6.1 | Rest of the World by Country Analysis |
9.6.2 | Russia |
9.6.3 | Saudi Arabia |
9.6.4 | Israel |
9.6.5 | South Africa |
9.6.6 | United Arab Emirates (UAE) |
9.6.7 | Rest of RoW |
10.1 | Carestream Health |
10.1.1 | Overview |
10.1.2 | Product Mapping |
10.1.3 | Overall Summary |
10.1.4 | SWOT Analysis |
10.2 | Dilon Diagnostics |
10.2.1 | Overview |
10.2.2 | Product Mapping |
10.2.3 | Overall Summary |
10.2.4 | SWOT Analysis |
10.3 | Esaote |
10.3.1 | Overview |
10.3.2 | Product Mapping |
10.3.3 | Overall Summary |
10.3.4 | SWOT Analysis |
10.4 | Fujifilm Holdings Corporation |
10.4.1 | Overview |
10.4.2 | Product Mapping |
10.4.3 | Financials |
10.4.3.1 | Financial Summary |
10.4.4 | SWOT Analysis |
10.5 | Gamma Medica Inc. |
10.5.1 | Overview |
10.5.2 | Product Mapping |
10.5.3 | Overall Summary |
10.5.4 | SWOT Analysis |
10.6 | GE Healthcare |
10.6.1 | Overview: GE Healthcare |
10.6.2 | Overview: General Electric |
10.6.3 | Product Mapping |
10.6.4 | Financials |
10.6.4.1 | Finacial Summary |
10.6.5 | SWOT Analysis |
10.7 | Hitachi Medical Corporation |
10.7.1 | Overview: Hitachi Medical Corporation |
10.7.2 | Overview: Hitachi |
10.7.3 | Financials |
10.7.3.1 | Finacial Summary |
10.7.4 | SWOT Analysis |
10.8 | Hologic Inc. |
10.8.1 | Overview |
10.8.2 | Product Mapping |
10.8.3 | Financials |
10.8.3.1 | Financial Summary |
10.8.4 | SWOT Analysis |
10.9 | Konica Minolta |
10.9.1 | Overview |
10.9.2 | Product Mapping |
10.9.3 | Financials |
10.9.3.1 | Financial Summary |
10.9.4 | SWOT Analysis |
10.10 | Neusoft Medical |
10.10.1 | Overview: Neusoft Medical |
10.10.2 | Overview: Neusoft Corporation |
10.10.3 | Product Mapping |
10.10.4 | Financials |
10.10.4.1 | Financial Summary |
10.10.5 | SWOT Analysis |
10.11 | Philips Group |
10.11.1 | Overview |
10.11.2 | Product Mapping |
10.11.3 | Financials |
10.11.3.1 | Financial Summary |
10.11.4 | SWOT Analysis |
10.12 | Samsung Medison Co. Ltd. |
10.12.1 | Overview: Samsung Medison Co. Ltd. |
10.12.2 | Overview: Samsung Electronics Co. Ltd. |
10.12.3 | Product Mapping |
10.12.4 | Financials |
10.12.4.1 | Financial Summary |
10.12.5 | SWOT Analysis |
10.13 | Shimadzu Corporation |
10.13.1 | Overview |
10.13.2 | Product Mapping |
10.13.3 | Financials |
10.13.3.1 | Financial Summary |
10.13.4 | SWOT Analysis |
10.14 | Siemens Healthineers |
10.14.1 | Overview: Siemens Healthineers |
10.14.2 | Overview: Siemens |
10.14.3 | Product Mapping |
10.14.4 | Financials |
10.14.4.1 | Financial Summary |
10.14.5 | SWOT Analysis |
10.15 | Toshiba Medical Corporation |
10.15.1 | Overview: Toshiba Medical Corporation |
10.15.2 | Overview: Canon Inc. |
10.15.3 | Product Mapping |
10.15.4 | Financials |
10.15.4.1 | Financial Summary |
10.15.5 | SWOT Analysis |
10.16 | Analogic Corporation |
10.16.1 | Overview |
10.17 | Aurora Imaging Technology, Inc. |
10.17.1 | Overview |
10.18 | Bruker Corporation |
10.18.1 | Overview |
10.19 | Koning Corporation |
10.19.1 | Overview |
10.20 | MR Solutions |
10.20.1 | Overview |
10.21 | NCD Company |
10.21.1 | Overview |
10.22 | Perkin Elmer |
10.22.1 | Overview |
10.23 | Planmed Oy |
10.23.1 | Overview |
10.24 | Spectrum Medical Imaging |
10.24.1 | Overview |
10.25 | UMG/DEL Medical Imaging |
10.25.1 | Overview |
10.26 | Varian Medical Systems |
10.26.1 | Overview |
1 | Difference Between Screening Test and Diagnostic Test |
2 | Cancer Types Patient Data |
3 | Imaging Procedures & Their Approximate Effective Radiation Doses |
4 | New Product Launches and Developments |
5 | Patents, Approvals and Certifications |
6 | Business Expansions/Contracts |
7 | Collaborations, Joint Ventures & Partnerships |
8 | Other Strategies |
9 | Patent Landscape |
10 | Consortiums, Associations and Regulatory Bodies |
11 | Global Cancer Imaging Systems Market by Product, 2016-2025 ($Million) |
12 | Mammogram Screening Reported, 2014-2015 |
13 | APAC Mammogram Units Reported, 2014 |
14 | CT Scan Volume Data, 2015 |
15 | MRI (Some of the National Average Billings) |
16 | MRI Scan Volume data, 2015 |
17 | Breast Cancer Patient Data in Top Countries, (2014-2021) |
18 | The U.S. Breast Screening Data |
19 | Lung Cancer Patient Data in Top Countries, (2014-2021) |
20 | Summary of prostate cancer imaging modalities |
21 | Prostate Cancer Patient Data in Top Countries, (2014-2021) |
22 | Colorectal Cancer Patient Data in Top Countries, (2014-2021) |
23 | Liver Cancer Patient Data in Top Countries, (2014-2021) |
24 | Stomach Cancer Patient Data in Top Countries, (2014-2021) |
25 | Total Number of Hospitals |
26 | Total Number of U.S. Outpatient Diagnostic Imaging Centres |
27 | CT installation in ambulatory care services |
28 | MRI installation in ambulatory care services |
29 | European Key Market Players |
30 | Installed Modalities in India, 2015 |
31 | Overview: Carestream Health |
32 | Overview: Dilon Diagnostics |
33 | Overview: Esaote |
34 | Overview: Fujifilm Holdings Corporation |
35 | Overview: Gamma Medica Inc. |
36 | Overview: GE Healthcare |
37 | Overvie: General Electric |
38 | Overview: Hitachi Medical Corporation |
39 | Overview: Hitachi |
40 | Overview: Holgic Inc. |
41 | Overview: Konica Minolta |
42 | Overview: Neusoft Medical |
43 | Overview: Neusoft Corporation |
44 | Overview: Philips Group |
45 | Overview: Samsung Medison Co. Ltd. |
46 | Overview: Samsung Electronics Co. Ltd. |
47 | Overview: Shimadzu Corporation |
48 | Overview: Siemens Healthineers |
49 | Overview: Siemens |
50 | Overview: Toshiba Medical Corporation |
51 | Overview: Canon Inc. |
52 | Overview: Analogic Corporation |
53 | Overview: Aurora Imaging Technology, Inc. |
54 | Overview: Bruker Corporation |
55 | Overview: Koning Corporation |
56 | Overview: MR Solutions |
57 | Overview: NCD Company |
58 | Overview: Perkin Elmer |
59 | Overview: Planmed Oy |
60 | Overview: Spectrum Medical Imaging |
61 | UMG/DEL Medical Imaging |
62 | Varian Medical Systems |
1 | Cancer Imaging Systems Drivers & Challenges |
2 | Cancer Imaging Systems Market Share by Product, 2016 |
3 | Cancer Imaging Systems Market Share by Product, 2025 |
4 | Global Cancer Imaging Systems Market by Product Growth Rate (2017-2025) |
5 | Cancer Imaging Systems Market Share by Application, 2016 |
6 | Cancer Imaging Systems Market Share by Application, 2025 |
7 | Global Cancer Imaging Systems Market by Application Growth Rate (2017-2025) |
8 | Cancer Imaging Systems Market Share by End-User, 2016 |
9 | Cancer Imaging Systems Market Share by End-User, 2025 |
10 | Global Cancer Imaging Systems Market by End-User Growth Rate (2017-2025) |
11 | Global Cancer Imaging Systems Market Share by Region, 2016 |
12 | Global Cancer Imaging Systems Market Share by Region, 2025 |
13 | Global Cancer Imaging Systems Market by Geographical Growth Rate (2017-2025) |
14 | Global Cancer Imaging Systems Market by Countries Growth Rate (2017-2025) |
15 | Global Cancer Imaging Systems Market Value by Region, 2016 & 2025 ($Million |
16 | Global Cancer Imaging Systems Market Segmentation |
17 | Research Methodology |
18 | Data Traingulation |
19 | Key Data Points From Secondary Sources |
20 | Secondary Data Sources |
21 | Key Data Points From Primary Sources |
22 | Top-Down Approach (Segmental Analysis) |
23 | Bottom-Up Approach (Segmental Analysis) |
24 | Assumptions and Limitations |
25 | Data and Prediction Modelling |
26 | Important Facts |
27 | Estimated Number of New Cases of Cancer and Deaths by Gender, U.S., 2017 |
28 | Discovery of Medical Imaging Modalities |
29 | Potential Benefits & Risks of Medical Imaging |
30 | Market Dynamics |
31 | Market Drivers |
32 | Market Challenges |
33 | Market Opportunities |
34 | Recent Market Development Strategy Snapshot Analysis |
35 | Key Market Developments & Strategies |
36 | Emerging Trends in Medical Imaging Technology |
37 | Diagnostic Imaging Market Share by Company, 2015 |
38 | Diagnostic Imaging Market Share by Company, 2016 |
39 | Growth Share Matrix |
40 | Global Cancer Imaging Systems Market by Product |
41 | Analog Mammography Cancer Imaging Systems Market, 2016-2025 ($Million) |
42 | Global Cancer Imaging Analog Mammography Market by Region, 2016-2025 ($Million) |
43 | Full Field Digital Mammography Cancer Imaging Systems Market, 2016-2025 ($Million) |
44 | Global Cancer Imaging Full Field Digital Mammography Market by Region, 2016-2025 ($Million) |
45 | Digital Breast Tomosynthesis Cancer Imaging Systems Market, 2016-2025 ($Million) |
46 | Global Cancer Imaging Digital Breast Tomosynthesis Market by Region, 2016-2025 ($Million) |
47 | Pros & Cons of Conventional Mammography Technique |
48 | Pros & Cons of Digital Mammography |
49 | Tumor Size Indicators |
50 | Palpable Nodes Indicators |
51 | Metastasis Indicators |
52 | Mammography Units per Million Population (OECD countries) 2015 |
53 | Computed Tomography Cancer Imaging Systems Market, 2016-2025 ($Million) |
54 | Global Cancer Imaging Computed Tomography Market by Region, 2016-2025 ($Million) |
55 | Use of CT in cancer imaging |
56 | CT Units per Million Population (OECD countries) 2015 |
57 | Molecular Breast Imaging Cancer Imaging Systems Market, 2016-2025 ($Million) |
58 | Global Cancer Imaging Molecular Breast Imaging Market by Geography, 2016-2025 ($Million) |
59 | Breast Density |
60 | Causes for Growth of Dense Breast Tissues |
61 | Certain Pros & Cons of Molecular Breast Imaging (MBI) |
62 | Magnetic Resonance Imaging Cancer Imaging Systems Market, 2016-2025 ($Million) |
63 | Global Cancer Imaging Magnetic Resonance Imaging Market by Geography, 2016-2025 ($Million) |
64 | Types of MRI |
65 | MRI Units Per Million Population (OECD countries 2015) |
66 | Positron Emission Tomography Cancer Imaging Systems Market, 2016-2025 ($Million) |
67 | Global Cancer Imaging Positron Emission Tomography Market by Geography, 2016-2025 ($Million) |
68 | Uses of PET Scan |
69 | Some of the Tracers Used in PET |
70 | Application Area of PET (%) |
71 | PET Scanner |
72 | PET Scan Image |
73 | Pros & Cons of PET |
74 | Ultrasound Cancer Imaging Systems Market, 2016-2025 ($Million) |
75 | Global Cancer Imaging Ultrasound Market by Geography, 2016-2025 ($Million) |
76 | Common Ultrasound Imaging Procedures |
77 | Advantages & Disadvantages of Ultrasound |
78 | Other Products in the Cancer Imaging Systems Market, 2016-2025 ($Million) |
79 | Global Cancer Imaging Other Products Market by Geography, 2016-2025 ($Million) |
80 | Global Cancer Imaging Market by Cancer Types |
81 | Global Cancer Imaging Systems Market by Application, 2016-2025 ($Million) |
82 | Breast Cancer Application Cancer Imaging Systems Market, 2016-2025 ($Million) |
83 | Percentage of New Breast Cancer Cases by Age Group (2010-2014) |
84 | Breast Cancer Patient Data (2016) |
85 | Imaging Modalities Used for Breast Cancer |
86 | Lung Cancer Application Cancer Imaging Systems Market, 2016-2025 ($Million) |
87 | Stages of Non-Small Cell Lung Cancer |
88 | Imaging Modalities Used for Lung Cancer |
89 | Prostate Cancer Application Cancer Imaging Systems Market, 2016-2025 ($Million) |
90 | Prostate Cancer Patient Data (2016) |
91 | Colorectal Cancer Application Cancer Imaging Systems Market, 2016-2025 ($Million) |
92 | Imaging Modalities Used for Colorectal Cancer |
93 | Colorectal cancer by Age |
94 | Colorectal Cancer Patient Data (2016) |
95 | Liver Cancer Application Cancer Imaging Systems Market, 2016-2025 ($Million) |
96 | Liver Cancer Patient Data (2016) |
97 | Imaging Modalities Used for Liver Cancer |
98 | Other Cancers Application Cancer Imaging Systems Market, 2016-2025 ($Million) |
99 | Cancer imaging Systems Market by End-User |
100 | Global Cancer Imaging Systems Market by End-Users, 2016-2025 ($Million) |
101 | Hospitals Cancer Imaging Systems Market, 2016-2025 ($Million) |
102 | Global Cancer Imaging Hospitals Market by Application, 2016-2025 ($Million) |
103 | Diagnostic Imaging Centers Cancer Imaging Systems Market, 2016-2025 ($Million) |
104 | Global Cancer Imaging Diagnostic Imaging Centers Market by Application, 2016-2025 ($Million) |
105 | Other End-User Cancer Imaging Systems Market, 2016-2025 ($Million) |
106 | Global Cancer Imaging Others Market by Application, 2016-2025 ($Million) |
107 | Global Scenario |
108 | Global Cancer Imaging Systems Market by Region, 2016-2025 ($Million) |
109 | North America Cancer Imaging Systems Market, 2016-2025 ($Million) |
110 | North America Cancer Imaging Systems Market by Country, 2016-2025 ($Million) |
111 | U.S. Cancer Imaging System Market, 2016-2025 ($Million) |
112 | Canada Cancer Imaging System Market, 2016-2025 ($Million) |
113 | Cancer Patient Data by Cancers Type in the U.S. (2016 |
114 | Cancer Patient Data by Cancers Type in Canada (2016) |
115 | Europe Cancer Imaging Systems Market, 2016-2025 ($Million) |
116 | Europe Cancer Imaging Systems Market by Country, 2016-2025($Million) |
117 | Germany Cancer Imaging System Market, 2016-2025 ($Million) |
118 | France Cancer Imaging System Market, 2016-2025 ($Million) |
119 | U.K. Cancer Imaging System Market, 2016-2025 ($Million) |
120 | Italy Cancer Imaging System Market, 2016-2025 ($Million) |
121 | Spain Cancer Imaging System Market, 2016-2025 ($Million) |
122 | Netherlands Cancer Imaging System Market, 2016-2025 ($Million) |
123 | Belgium Cancer Imaging System Market, 2016-2025 ($Million) |
124 | Rest of Europe Cancer Imaging System Market, 2016-2025 ($Million) |
125 | Key Market Drivers in the European Countries |
126 | Denmark-Cancer Patient Data |
127 | Germany-Cancer Patient Data (2016 |
128 | France-Cancer Patient Data (2016) |
129 | Italy- Cancer Patient Data (2016) |
130 | Market Dynamics (Europe) |
131 | Asia-Pacific Cancer Imaging Systems Market , 2016-2025 ($Million) |
132 | Asia-Pacific Cancer Imaging Systems Market by Country, 2016-2025($Million) |
133 | Japan Cancer Imaging System Market, 2016-2025 ($Million) |
134 | China Cancer Imaging System Market, 2016-2025 ($Million) |
135 | Australia Cancer Imaging System Market, 2016-2025 ($Million) |
136 | South Korea Cancer Imaging System Market, 2016-2025 ($Million) |
137 | India Cancer Imaging System Market, 2016-2025 ($Million) |
138 | Malaysia Cancer Imaging System Market, 2016-2025 ($Million) |
139 | Japan Cancer Patient Data, 2016 |
140 | China-Cancer Patient Data, 2016 |
141 | Installed Modalities in India, 2015 |
142 | India-Cancer Patient Data,2016 |
143 | Latin America Cancer Imaging Systems Market , 2016-2025 ($Million) |
144 | Latin America Cancer Imaging Systems Market by Country, 2016-2025($Million) |
145 | Brazil Cancer Imaging System Market, 2016-2025 ($Million) |
146 | Mexico Cancer Imaging System Market, 2016-2025 ($Million) |
147 | Rest of Latin America Cancer Imaging System Market, 2016-2025 ($Million) |
148 | Rest of World Cancer Imaging Systems Market , 2016-2025 ($Million) |
149 | RoW Cancer Imaging Systems Market by Country, 2016-2025($Million) |
150 | Russia Cancer Imaging System Market, 2016-2025 ($Million) |
151 | Saudi Arabia Cancer Imaging System Market, 2016-2025 ($Million) |
152 | Israel Cancer Imaging System Market, 2016-2025 ($Million) |
153 | South Africa Cancer Imaging System Market, 2016-2025 ($Million) |
154 | United Arab Emirates (UAE) Cancer Imaging System Market, 2016-2025 ($Million) |
155 | Rest of RoW Cancer Imaging System Market, 2016-2025 ($Million) |
156 | Qatar Cancer Patient Data,2016 |
157 | Israel-Cancer Patient Data,2016 |
158 | Egypt-Cancer Patient Data,2016 |
159 | Saudi Arabia- Cancer Patient Data ,2016 |
160 | Carestream Health: Product Mapping |
161 | Carestream Health: SWOT Analysis |
162 | Dilon Diagnostics: Product Mapping |
163 | Dilon Diagnostics: SWOT Analysis |
164 | Esaote: Product Mapping |
165 | Esaote: SWOT Analysis |
166 | Fujifilm Holdings Corporation: Product Mapping |
167 | Fujifilm Holdings Corporation: Overall Financials (2014-2016) |
168 | Fujifilm Holdings Corporation: Net Revenue by Business Segment (2014-2016) |
169 | Fujifilm Holdings Corporation: Net Revenue by Business Sub-segment (2016) |
170 | Fujifilm Holdings Corporation: Net Revenue by Region (2014-2016) |
171 | Fujifilm Holdings Corporation: SWOT Analysis |
172 | Gamma Medica Inc.: Product Mapping |
173 | Gamma Medica Inc.: SWOT Analysis |
174 | General Electric: Product Mapping |
175 | General Electric: Overall Financials (2014-2016) |
176 | General Electric: Net Revenue by Business Segment (2014-2016) |
177 | General Electric: Net Revenue by Business Sub-Segment (2016) |
178 | General Electric: Net Revenue by Region (2014-2016) |
179 | General Electric: SWOT Analysis |
180 | Hitachi: Product Mapping |
181 | Hitachi: Overall Financials (2014-2016) |
182 | Hitachi: Net Revenue by Region (2014-2016) |
183 | Hitachi: Net Revenue by Business Segment (2014) |
184 | Hitachi: Net Revenue by Business Segment (2015-2016) |
185 | Hitachi: SWOT Analysis |
186 | Hologic Inc.: Product Mapping |
187 | Hologic Inc.: Overall Financials (2014-2016) |
188 | Hologic Inc.: Net Revenue by Business Segment (2014-2016) |
189 | Hologic Inc.: Net Revenue by Region (2014-2016) |
190 | Hologic Inc.: SWOT Analysis |
191 | Konica Minolta: Product Mapping |
192 | Konica Minolta: Overall Financials (2014-2016) |
193 | Konica Minolta: Net Revenue by Business Segment (2014-2016) |
194 | Konica Minolta: Net Revenue by Geography (2014-2016) |
195 | Konica Minolta: Net Revenue by Geography (2014-2016) |
196 | Neusoft Corporation: Product Mapping |
197 | Neusoft Corporation: Overall Financials (2014-2016) |
198 | Neusoft Corporation: SWOT Analysis |
199 | Philips Group: Product Mapping |
200 | Philips Group: Overall Financial Performance (2014-2016) |
201 | Philips Group: Net Revenue by Business Segment (2015-2016) |
202 | Philips Group: Net Revenue by Geography (2014-2016) |
203 | Philips Group: Net Revenue by Business segment (2014) |
204 | Philips Group: Diagnostics & Treatment Sub-Segment% (2016) |
205 | Philips Group: SWOT Analysis |
206 | Samsung: Product Mapping |
207 | Samsung: Overall Financials (2014-2016) |
208 | Samsung: Net Revenue by Business Segment (2014-2016) |
209 | Samsung: Net Revenue by Region (2014-2016) |
210 | Samsung: SWOT Analysis |
211 | Shimadzu Corporation: Product Mapping |
212 | Shimadzu Corporation: Overall Financials (2014-2016) |
213 | Shimadzu Corporation: Net Revenue by Business Segment (2014-2016) |
214 | Shimadzu Corporation: Net Revenue by Geography (2014-2016) |
215 | Shimadzu Corporation: SWOT Analysis |
216 | Siemens Healthineers: Product Mapping |
217 | Siemens Healthineers: Overall Financials (2014-2016) |
218 | Siemens Healthineers: Net Revenue by Region (2014-2016) |
219 | Siemens Healthineers: Net Revenue by Business Segment (2014-2016) |
220 | Siemens Healthineers: SWOT Analysis |
221 | Canon Inc. (Toshiba Medical Corporation): Product Mapping |
222 | Canon Inc. (Toshiba Medical Corporation): Overall Financials (2014-2016) |
223 | Canon Inc. (Toshiba Medical Corporation): Net Revenue by Business Segment (2014-2016) |
224 | Canon Inc. (Toshiba Medical Corporation): Net Revenue by Region (2014-2016) |
225 | Canon Inc. (Toshiba Medical Corporation): SWOT Analysis |
Report Description
The cancer imaging system plays a significant role in the detection of cancer as it provides a detailed insight into the exact location and extent of the disease. It also provides detailed information about the structural or cancer related changes. The cancer imaging system not only helps in the detection of the tumour, but also helps in the evaluation of therapeutic & post-therapeutic changes, complications of treatments and follow-up for finding the early detection of recurrence. The medical experts believe that most of the cancer types can be dealt effectively if detected early. Moreover, the emerging methods of molecular imaging which combine the traditional imaging technology and nuclear medicine techniques can also be used to obtain more detailed information about abnormalities, including their distinct metabolism.
This research study includes an extensive analysis of the global cancer imaging systems market, by product, application, end-user and geographical regions, allowing the researcher to develop a comprehensive outlook of the market. Each of these segments have been analyzed on the basis of their current and future market size, considering the macro and micro environmental factors.
The market report presents a detailed and investigative study of the entire market and provides a comprehensive insight into various forms of developments, trends and the key market participants. While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section on competitive landscape, market share analysis, growth share matrix, competitive benchmarking, and the position of the competitors within the global cancer imaging systems market.
The key players which have significant contributions to the cancer imaging systems market are Siemens Healthineers, GE Healthcare, Hologic Inc., Toshiba Medical Corporation, Hitachi Medical Systems, Gamma Medica Inc., Philips Healthcare, Carestream Health, Fujifilm Holdings Corporation, Konica Minolta, Neusoft Medical, Samsung Medison Co. Ltd and Shimadzu Corporation among others.
Key Questions Answered in this Report
The following key questions have been addressed in the report:
• What are the major market drivers, challenges and opportunities of the global cancer imaging systems market?
• How the cancer imaging systems evolve and what is its scope in the future?
• What are the market shares of the leading segments and sub-segments of the global cancer imaging systems market in 2016 and 2025?
• How will each segment of the global cancer imaging systems market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2025?
• How will the market share of the leading companies change in 2017 and which country will lead the market in 2017?
• How will the industry evolve during the forecast period between 2017 and 2025?
• What are the key developmental strategies implemented by the key players to stand out in this market?
• How the market has been segmented on the basis of products, application, end-user and region?
• Which product, application and end-user will dominate the global cancer imaging systems market by the end of the forecast period and which one is growing at the highest CAGR during the forecast period 2017-2025?
• What will be the growth rate of different segments during the forecast period? Which is the leading segment by product, application, end-user and region?
• Who are the key players for the cancer imaging systems market?
• Which geographical region will lead the global cancer imaging systems market by the end of the forecast period?
• Which country is growing at the highest CAGR during the forecast period?
Market Overview
Cancer is one of the leading causes of mortality and morbidity worldwide and according to World Health Organization (WHO), the number of new cases is expected to rise by about 70% over the next 2 decades. Cancer is a broad term for a class of disease characterized by abnormal cells that grow and invade healthy cells in the body. The cancer begins in the cells which are the basic building blocks that make up tissue. It begins with genetic changes impairing this orderly process. Cells start to grow uncontrollably and these cells may form a mass termed as tumor.
The cancer imaging systems market is growing at an exponential rate with the increasing incidence of various types of cancer and active research and developmental activities dedicated to the continuous advancement in the imaging modalities. With the rising incidence of various types of cancer such as breast, lung, prostate and colorectal, cancer is the primary responsible factor for the growth of cancer imaging systems market. Furthermore, advancements in digital imaging techniques, growing awareness among the patients about early detection of cancer, and active support of the government has boosted the overall growth of this market. Moreover, the expansion of digital imaging modalities to newer clinical areas, active research and developmental activities in medical imaging, rapid transition of hospitals to promote automatic workflow integration in their current work environment and rising installation base of advanced medical imaging tools in various multispecialty hospitals, is further expected to accentuate the growth of this market in the near future.
However, certain restraining factors such as side effects of radiation exposure, shortage of skilled professionals and high installation cost of cancer imaging systems might hamper the growth of this market. Similarly, unfavorable taxation and lack of favorable reimbursement policies from the European and Asian governments have also negatively impacted the growth of this market.
The new range of companies are striving hard to file patents and get approvals from the regulatory bodies in this growing market and launch innovative products, while the established companies are busy in acquiring companies and partnerships with other ecosystem players.
The global cancer imaging systems is expected to reach $11 billion by 2025. The cancer imaging market broadly focuses on major cancer indications (breast cancer, lung cancer, colorectal cancer and prostate cancer, among others) and various imaging modalities (mammography, MRI and positron emission tomography, among others). The cancer imaging systems have become one of the major potential tools in early cancer detection and diagnostics radiology and also help in decreasing the mortality rate due to cancer.
The product segment of this market comprises of various cancer imaging modalities such as analog mammography, full field digital mammography, digital breast tomosynthesis (DBT), ultrasound, computed tomography (CT), molecular breast imaging (MBI), magnetic resonance imaging (MRI) and positron emission tomography (PET), among others. The ultrasound acquired the highest market value and growing at a CAGR of 3.7%. The reason for such strong market share is attributed to the advantages provided by ultrasound system such as precision in identifying the nature of lesion, less expensive and free from exposure to radiations, active participation of government and industry players in continuous technological development, among others.
The application segment of this market comprises of oncology indications such as breast, lung, colorectal, prostate, liver and other cancers. The breast cancer acquired the highest market value. However, lung cancer is growing at the highest CAGR 5.4%. The reason for such strong market share is attributed to the rising incidence rate of breast cancer among the women all over the world.
The end user segment comprises of hospitals and diagnostic imaging centers, among others. The hospitals segment acquired the highest market value and growing at a CAGR of 4.2%. However, the others segment comprising of physician office and ambulatory services, among others, is growing at the highest CAGR of 6%. Hospitals, which are the major buyers of cancer imaging systems are increasing significantly. Due to the growing geriatric population, rising prevalence of cancer and continuous technological advancements in imaging modalities, there is an increasing demand of imaging technologies both from the health workers and patients, in order to meet the growing volume of cancer patients.
North America is dominating the market in 2016 and is growing at a CAGR of 4.3% during the forecast period. While, Latin America is growing at a CAGR of 6.7% from 2017 to 2025. The key players in the global cancer imaging systems market are Siemens Healthineers, Hologic Corporation, GE Healthcare, Philips Healthcare, Toshiba Medical Corporation, Hitachi Medical, Konica Minolta, Carestream Health and Yangzhou Kindsway Biotech Co. Ltd., among others. The market players are getting into the strategies such as collaborations, partnership & joint ventures, business expansion & contracts, product launches & developments, patents approvals & certifications, and mergers & acquisitions, among others.
The product launch & development strategy dominates the market, followed by regulatory approvals & certification strategy. The companies are busy in new product launches and developments in order to sustain their position and to enhance their business strength and outreach. The market is growing at a very high rate with a strong potential and sustainability. The market players are actively involved in the research and development of more technological advanced imaging modalities to save time, money and life. Along with the existing drivers of the market, the manufacturing of low cost imaging systems, automated image analysis techniques and fusion of two or three imaging modalities are some of the potential opportunities for the market players to sustain a strong position in the cancer imaging systems market.
Global Cancer Imaging Systems Market - Analysis and Forecast (2017-2025)
Focus on Products (Analog Mammography, Digital Breast Tomosynthesis, Molecular Breast Imaging, MRI, CT, PET, and others), Cancer Types, End Users, 26 Country Analysis, Patent Analysis, Market Share Analysis, Growth Share Matrix, and Competitive Landscape